Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
29.01.24
/
50%
€21.00
Target price
29.01.25
€28.68
Performance (%)
-42.86%
End price
30.01.25
€12.00
Summary
This prediction ended on 30.01.25 with a price of €12.00. Massive losses of -42.86% were the result for the BUY prediction by The_Goldman_Sachs_Gr. The_Goldman_Sachs_Gr has a follow-up prediction for Myriad Genetics where he still thinks Myriad Genetics is a Buy. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | -2.475% | -2.475% | -56.703% |
| iShares Core DAX® | -4,93 % | -11,98 % | -3,49 % |
| iShares Nasdaq 100 | -2,63 % | -2,22 % | 13,78 % |
| iShares Nikkei 225® | -4,73 % | -10,90 % | 19,71 % |
| iShares S&P 500 | -2,54 % | -3,54 % | 8,88 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
In the thread Trading Myriad Genetics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten